Answers are grounded in this paper and cite their sources.
Long-acting injectable buprenorphine treatment is promoted as an innovative alternative to traditional opioid agonist treatment, offering people in treatment greater stability, reduced dependence on daily dosing routines, and the possibility of reclaiming a sense of normalcy. Yet little is known about how such promises of freedom take shape and manifest in the lifeworlds of people in treatment. Drawing on semistructured interviews with people receiving treatment with long-acting buprenorphine in a Danish opioid agonist treatment clinic, this article examines how the treatment changes participants’ practical horizons of possibilities and pathways to recovery in different ways. While long-acting injectable buprenorphine theoretically has the potential to redirect an everyday orientation away from opioids, our findings show that the capacity to translate this freedom into meaningful changes in daily life is unevenly distributed. Using a phenomenological framework attuned to questions of freedom and recovery from opioid dependence, we identify three distinct ways in which participants reconfigure their horizons of possibility through different trajectories of re-worlding in long-acting injectable buprenorphine treatment: (a) returning to familiar worlds, (b) building new worlds, and (c) living in in-between worlds. We conclude that social backgrounds and histories of marginalization of people in treatment shape how their existential paths toward living beyond constraints of opioid dependence, and that focusing on the enactments of freedom and recovery as differentiated process of re-worlding bring necessary nuance to the ideas of freedom associated with long-acting injectable buprenorphine treatment.
No takes yet. Share an insight, caveat, or question.
Kristensen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: